title: Comparative pharmacokinetic study of paclitaxel and docetaxel in streptozotocin-induced diabetic rats.
abstract: The pharmacokinetics of paclitaxel and docetaxel were compared in diabetic rats induced by streptozotocin (DMIS rats) and the impact of altered expression of cytochrome P450 3A (Cyp3A) and P-glycoprotein (P-gp) in the diabetic state. The pharmacokinetics of paclitaxel and docetaxel were determined after intravenous (5 mg/kg) and oral (30 and 40 mg/kg, respectively) administration to both groups and the mRNA expression levels of Cyp3A isozymes and Mdr1a and Mdr1b in the liver and small intestine were determined in control and DMIS rats. After intravenous administration, the AUC and clearance of paclitaxel and docetaxel were not significantly different in DMIS vs control rats. After oral administration, the AUC and C(max) of paclitaxel in DMIS rats were significantly greater than those in the control rats, whereas those of docetaxel was not changed significantly. The mRNA expression levels of hepatic Cyp3A1, Cyp3A9 and Mdr1b were significantly increased in DMIS compared with the control rats. In the intestine, Cyp3A62 expression decreased in the DMIS rats compared with the controls. Thus the pharmacokinetic changes of taxanes observed in the DMIS rats were attributed to changes in P-gp and Cyp3A, predominant factors that control the absorption of paclitaxel and docetaxel, respectively. It seemed that there were different susceptibilities to intestinal P-gp and Cyp3A between the two taxanes.
authors.affiliation: Division of Biopharmaceutics, College of Pharmacy, Kyung Hee University, Seoul, Korea.
authors.forename: Joo Hyun
authors.initials: JH
authors.lastname: Lee
authors.forename: Areum
authors.initials: A
authors.lastname: Lee
authors.forename: Ju-Hee
authors.initials: JH
authors.lastname: Oh
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Lee
mesh_terms: D018435:ATP Binding Cassette Transporter, Subfamily B / Q000235:genetics; D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D000077143:Docetaxel; D007413:Intestinal Mucosa / Q000378:metabolism; D007527:Isoenzymes / Q000235:genetics; D008099:Liver / Q000378:metabolism; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D043823:Taxoids / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D000097202:ATP-Binding Cassette Sub-Family B Member 4
chemical_list: D018435:ATP Binding Cassette Transporter, Subfamily B; D000970:Antineoplastic Agents; D051544:Cytochrome P-450 CYP3A; D000077143:Docetaxel; D007527:Isoenzymes; D017239:Paclitaxel; D012333:RNA, Messenger; D043823:Taxoids; D000097202:ATP-Binding Cassette Sub-Family B Member 4; C095122:multidrug resistance protein 3